Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study

Table 1 Presenting features of the studied patients

	Treated group (n = 14)		Untreated group (n = 9)
	Baseline	Post losartan	Baseline	Second biopsy
Females/males	4/14		1/8
Age (yr)	49.6±13
Hematocrit	45.2±3.59	44.1±3.85	48.8±4.66	47.8±4.15
White blood cells (K/mm3)	6.66±1.41	6.71±1.67	5.98±0.95	5.78±1.19
Platelets (K/mm3	227±80.8	246±90.7b	223±68	209±78.4
Glucose (g/L)	0.99±0.38	1±0.29	0.95±0.1	1.01±0.06
Blood urea nitrogen (g/L)	0.31±0.06	0.32±0.06	0.28±0.07	0.25±0.04
Creatinine (mg/dL)	0.88±0.07	0.95±0.11	0.99±0.07	0.96±0.12
Total bilirubin (mg/dL)	1±0.53	1.08±0.63	1.35±0.58	1.19±0.58
Alkaline phosphatase (IU/L)	253±118	269±68.9	264±93.4	349±134
Alanine aminotransferase (IU/L)	90.5±66	91.9±47.6	264±167a	169±124
Aspartate aminotransferase (IU/L)	65.3±41	67±40.9	161±97.8a	130±84.5
Cholesterol (mg/dL)	157±36.4	161±42.6	166±38.1	169±39.2
Albumin (g/dL)	4.12±0.32	4.43±0.24b	4.32±0.56	4.32±0.5
Globulins (g/dL)	3.64±0.53	3.77±0.45	3.74±0.63	3.91±0.63
G glutamyl transpeptidase (IU/ L)	63.2±47.9	74.5±53.7	194±178a	217±214
Prothrombin time (%)	103±19.3	106±17.4	107±8.19	97±9.83
KPTT (s)	32.6±3.38	39.6±18.7	37.8±6.99	34.5±2.38

Results are expressed as mean±SD.

^aP<0.05 in comparison with baseline measurements in the treated group.

^bP<0.01 in comparison with baseline measurements in the treated group.